Enlivex Ltd. has announced a significant change in its share structure, implementing a reverse share split of its ordinary shares at a ratio of 1-for-16. This decision, made during an Extraordinary General Meeting of Shareholders on October 22, 2026, is set to take effect on October 27, 2026. The reverse split aims to consolidate shares and enhance the stock's marketability on the Nasdaq Capital Market.
The company, which operates in the finance services sector, believes that this move will provide a more favorable trading environment for its shares. Following the reverse split, every 16 ordinary shares will automatically combine into one ordinary share, reducing the number of authorized shares from 158,333,333 to 9,895,833. The par value of each share will increase from NIS 6.00 to NIS 96.00, and the number of issued and outstanding shares will decrease from 24,511,905 to approximately 1,531,995.
Background
Enlivex Ltd. is a company incorporated in Israel, listed on the Nasdaq under the ticker symbol ENLV. The company is classified under the SIC code 6199, which pertains to finance services. Enlivex has undergone several name changes in its history, previously known as Enlivex Therapeutics Ltd. and Bioblast Pharma Ltd. The company focuses on advancing its clinical-stage immunotherapy, Allocetra™, targeting inflammatory conditions associated with aging.
What the Filing Says
According to the filing dated October 22, 2026, Enlivex's shareholders approved the reverse share split, which will be implemented as soon as practicable. The filing states, "The ordinary shares will begin trading on a split-adjusted basis on the Nasdaq Capital Market on October 27, 2026." This change is expected to streamline the company's share structure and improve its market presence.
Impact
The reverse share split may affect various stakeholders, including current shareholders, potential investors, and the company's management. Shareholders will see a reduction in the number of shares they own, but their overall ownership percentage will remain unchanged, barring adjustments for fractional shares. This strategic move may also influence how the market perceives Enlivex, potentially attracting new investors looking for more stable stock prices.
What's Next
The filing does not specify what happens next beyond the implementation of the reverse split. However, the company has indicated that its transfer agent, VStock Transfer, LLC, will provide instructions to shareholders regarding the exchange of certificates for ordinary shares.